Johnson & Johnson (NYSE:JNJ) Shares Sold by Drive Wealth Management LLC

Drive Wealth Management LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 58.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,162 shares of the company's stock after selling 5,919 shares during the period. Drive Wealth Management LLC's holdings in Johnson & Johnson were worth $602,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. IFS Advisors LLC boosted its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $31,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after buying an additional 91 shares during the period. Finally, Activest Wealth Management purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $40,000. Institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company's stock, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Up 1.1 %

NYSE JNJ traded up $1.72 during trading on Thursday, hitting $152.87. The stock had a trading volume of 2,045,698 shares, compared to its average volume of 9,333,421. The stock has a 50 day simple moving average of $147.73 and a 200 day simple moving average of $156.10. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a market capitalization of $368.05 billion, a price-to-earnings ratio of 22.98, a P/E/G ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson's payout ratio is 74.59%.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective on the stock. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Finally, StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $170.44.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.